Meet the speaker #1 | Perturb 2027

With a career that includes directing the Icahn Genomics Institute and vice-chairing the Department of Immunology & Immunotherapy at the Mount Sinai Medical Center, get to know more about Dr. Brian Brown's career.

thumbnail depicting Brian Brown from the Icahn School of Medicine, speaker for Perturb 2027

With registrations open, it is time to start announcing the phenomenal line up of speakers that will take the stage at Perturb 2027!

Get to know the speaker: Brian Brown

Dr. Brian Brown is the Director of the Icahn Genomics Institute and Vice Chair of the Department of Immunology & Immunotherapy at the Mount Sinai Medical Center in New York City. He is also the Endowed Chair of Genetic Engineering. His research spans immune oncology, functional genomics, and gene and cell therapy. His lab focuses on uncovering the molecular and cellular programming of tissue and tumor immunity; using Perturb-map spatial functional genomics to identifying mechanisms of tumor microenvironment control and immunotherapy resistance. His group is also developing cell and tissue targeting technologies, based on spatial biology insights, for enhancing mRNA and nanoparticle drugs and CAR T cell therapeutics.

Early bird tickets for Perturb 2027: High-Content CRISPR Screening Conference are now available on the conference website

More news

Meet the speaker #6 | Perturb 2027

Professor at UCSF and a Core Investigator at the Arc Institute, get to know more about Dr. Gilbert, an early pioneer in repurposed CRISPR systems that are used to turn genes on and off (CRISPRa/i and CRISPRoff/on).

Meet the speaker #5 | Perturb 2027

Director of the Gladstone-UCSF Institute of Genomic Immunology and Professor in the UCSF Department of Medicine, get to know more about Dr. Marson’s research with genetically modified T cells.

Myllia announces newly formed board with industry leaders

Single-cell commercial leader Simone Günther, US biotech veteran Sandy Zweifach, and Werner Lanthaler (Wlanholding) join to guide Myllia's next phase of growth